16. June 2020 | 06:30 CET
Gilead, Teva, XPhyto - Global marketing potential
The best business models solve problems and are scalable. In this context, the healthcare sector is particularly interesting. The world's population has recently reached 7.8 billion people and for this reason solutions can meet a large potential market with users. Cross-border solutions are needed not only for pandemics, but also for diseases that are not mentioned in the mass media but are nevertheless of great importance. A successful market launch is of equal interest to those affected and investors.
time to read:
ISIN: CA98421R1055 , US8816242098 , US3755581036
Thin Film Solutions for a Mass Market
XPhyto from Canada announced yesterday that its German subsidiary Vektor Pharma TF GmbH has successfully incorporated peptide biosensors into the group's oral dissolvable thin film (ODF) technology. Together with its partner 3a-Diagnostics GmbH, the company is now developing pathogen-specific ODF biosensors for infectious diseases, including pandemic threats, the company announced.
"Successful incorporation of 3a's peptide biosensors into Vektor's ODF platform represents a significant technical milestone on the pathway to commercialization," Hugh Rogers, XPhyto CEO said in a statement. "This was a critical step that unlocks a pipeline of potential biosensor screening products."
3a biosensor screening tests have been developed for bacterial and viral infectious diseases, including influenza A, scarlet fever and periodontitis. The market is therefore large and further pandemic-focused biosensors are planned and developed, especially for coronavirus, swine flu and avian flu, according to the announcement. The partnership at product level therefore has potential. The market value of XPhyto is EUR 115.1 million.
Products for the Chinese market
Teva recently announced that the Chinese Food and Drug Administration has approved Austedo for the treatment of chorea associated with Huntington's disease and late dyskinesia in adults. According to the announcement, the company will independently market the drug Austedo in China. This follows the launch of the specialty drug Treanda on the Chinese market.
"We look forward to bringing more of the essential medicines in our portfolio to patients in China, and to fuel organic growth and expand our presence in this important market," said Gianfranco Nazzi of Teva, who is responsible for international markets. The market value of the company is around EUR 10.9 billion.
Licensing for 127 countries
Last week Gilead signed a license agreement with Dr. Reddy's Laboratories Ltd. for the registration, manufacture and sale of the antiviral drug Remdesivir. The product Remdesivir became known because it can be used to treat the current coronavirus. The contract covers a total of 127 countries, but an official approval for the marketing of Remdesivir in the respective country still has to be obtained from Dr. Reddy's.
In May 2020, the US Food and Drug Administration (FDA) granted emergency use authorization for Gilead's antiviral drug Remdesivir for the treatment of Covid-19. Under the non-exclusive license agreement, Dr. Reddy's will receive a technology transfer from Gilead for the manufacture of Remdesivir. Gilead's most recent market capitalization was approximately EUR 82.4 billion and this makes the company one of the heavyweights in the industry.